Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 26 references it cites were found in a registry or an index.

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

Abstract

Background Fluorouracil-based chemoradiotherapy is regarded as a standard perioperative treatment in locally advanced rectal cancer. We investigated the efficacy and safety of substituting fluorouracil with the oral prodrug capecitabine. Methods This randomised, open-label, multicentre, non-inferiority, phase 3 trial began in March, 2002, as an adjuvant trial comparing capecitabine-based chemoradiotherapy with fluorouracil-based chemoradiotherapy, in patients aged 18 years or older with pathological stage II-III locally advanced rectal cancer from 35 German institutions. Patients in the capecitabine group were scheduled to receive two cycles of capecitabine (2500 mg/m(2) days 1-14, repeated day 22), followed by chemoradiotherapy (50·4 Gy plus capecitabine 1650 mg/m(2) days 1-38), then three cycles of capecitabine. Patients in the fluorouracil group received two cycles of bolus fluorouracil (500 mg/m(2) days 1-5, repeated day 29), followed by chemoradiotherapy (50·4 Gy plus infusional fluorouracil 225 mg/m(2) daily), then two cycles of bolus fluorouracil. The protocol was amended in March, 2005, to allow a neoadjuvant cohort in which patients in the capecitabine group received chemoradiotherapy (50·4 Gy plus capecitabine 1650 mg/m(2) daily) followed by radical surgery and five cycles of capecitabine (2500 mg/m(2) per day for 14 days) and patients in the fluorouracil group received chemoradiotherapy (50·4 Gy plus infusional fluorouracil 1000 mg/m(2) days 1-5 and 29-33) followed…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70116-x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 516

Metadata

Authors
Hofheinz, R.-D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., Müller, L., Link, H., Moehler, M., Kettner, E., Fritz, E., Hieber, U., Lindemann, H. W., Grunewald, M., Kremers, S., Constantin, C., Hipp, M., Hartung, G., Gencer, D., Kienle, P., Burkholder, I., & Hochhaus, A.
Affiliations
  • Heidelberg University (DE)
  • Universitätsklinikum Tübingen (DE)
  • Westpfalz Klinikum (DE)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • Klinikum Magdeburg (DE)
  • Gemeinschaftsklinikum Mittelrhein (DE)
  • Klinikum Lippe (DE)
  • University Hospital Regensburg (DE)
  • German Cancer Research Center (DE)
  • Jena University Hospital (DE)
Corresponding author
Hofheinz, Ralf-Dieter
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2012-06
Volume
13
Issue
6
Pages
579-588
ISSN
1470-2045 (ISSN-L)
OpenAlex
W1967126296
Cited by
509
References
26
Citations by year
2026: 14 · 2025: 16 · 2024: 21 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 49 · 2019: 40 · 2018: 33 · 2017: 44 · 2016: 39 · 2015: 57 · 2014: 43 · 2013: 34 · 2012: 14
FWCI
23.41
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Regensburg Publication Server (University of Regensburg) (acceptedVersion)
Funders
Deutsches Krebsforschungszentrum
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords
locally advanced rectal cancer, capecitabine, 5-fluorouracil, chemoradiotherapy, adjuvant therapy, neoadjuvant therapy, overall survival, non-inferiority, oral prodrug, infusional fluorouracil, radical surgery, treatment safety
MeSH terms
Capecitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Deoxycytidine, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluorouracil, Follow-Up Studies, Germany, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Radiotherapy Dosage, Rectal Neoplasms, Survival Analysis, Treatment Outcome, Risk Assessment, Disease-Free Survival, Patient Selection, Cross-Over Studies, Maximum Tolerated Dose, Kaplan-Meier Estimate, Chemoradiotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(12)70116-x
The paper
Hofheinz, R.-D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., Müller, L., Link, H., Moehler, M., Kettner, E., Fritz, E., Hieber, U., Lindemann, H. W., Grunewald, M., Kremers, S., Constantin, C., Hipp, M., Hartung, G., Gencer, D., . . . Hochhaus, A. (2012). Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(12)70116-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.